HighGravityDataCurrent guidance
6 items
Becton Dickinson
Guidance from Becton Dickinson’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 6, 2026
Data checked
Aug 6, 2026
What changed in the Aug 6, 2026 release
Each item compared with the same item in the previous release (Apr 2, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Revenue growth (full year fiscal 2026) | for FY2026 | — | “toward the high end of its range” | Filing ↗ |
| Raised | Adjusted Diluted EPS | for FY2026 | “$12.35 to $12.65” | “$12.62 to $12.72” | Filing ↗ |
| New | Adjusted Diluted EPS Reported % Change | for FY2026 | — | “+6.1% to +6.9%” | Filing ↗ |
| Lowered | Illustrative Foreign Currency (FX) Impact | for FY2026 | “~+120 basis points” | “~+100 basis points” | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Revenue growth (full year fiscal 2026) | “toward the high end of its range” | for FY2026 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| Revenue Growth (FXN) | “Low single-digit” | for FY2026 | GAAP-tied | Feb 9, 2026 | 1 | Filing ↗ |
| Adjusted Diluted EPS | “$12.62 to $12.72” | for FY2026 | Company-defined | Feb 9, 2026 | 2 | Filing ↗ |
| Adjusted Diluted EPS Reported % Change | “+6.1% to +6.9%” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Reported % Change (Adjusted Diluted EPS) | “+4.7% to +7.2%” | for FY2026 | Company-defined | Feb 9, 2026 | 1 | Filing ↗ |
| Illustrative Foreign Currency (FX) Impact | “~+100 basis points” | for FY2026 | Company-defined | Feb 9, 2026 | 2 | Filing ↗ |
How one item moved
Adjusted Diluted EPS, for FY2025 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | No period |
|---|---|---|---|
| Adjusted Revenue Growth (FXN) | — | 4 statements | — |
| GAAP Revenues | — | 4 statements | — |
| Impact to organic revenue growth from expected decline in revenues in China and Bioscience and Pharma market dynamics | — | 1 statement | — |
| Organic Revenue Growth | — | 4 statements | — |
| Revenue growth (full year fiscal 2026) | 2 statements | — | — |
The full record for Becton Dickinson and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 6, 2026 | FY2026 Q3 | 0001628280-26-053790 | 4 | Open filing ↗ |
| Apr 2, 2026 | FY2026 Q2 | 0001628280-26-023185 | 0 | Open filing ↗ |
| Feb 9, 2026 | FY2026 Q1 | 0001628280-26-006182 | 4 | Open filing ↗ |
| Oct 9, 2025 | FY2025 Q4 | 0001628280-25-045106 | 1 | Open filing ↗ |
| Aug 7, 2025 | FY2025 Q3 | 0000010795-25-000069 | 8 | Open filing ↗ |
| May 1, 2025 | FY2025 Q2 | 0000010795-25-000036 | 9 | Open filing ↗ |
| Feb 5, 2025 | FY2025 Q1 | 0000010795-25-000019 | 5 | Open filing ↗ |
| Nov 7, 2024 | FY2024 Q4 | 0000010795-24-000078 | 7 | Open filing ↗ |
Not located in filing
1 value was detected in these releases but could not be matched to an exact sentence in the filing body, so it is not shown as guidance. We surface the count rather than drop it silently.
Show the 1 unmatched span
| Span | Why | Filed |
|---|---|---|
| Share repurchase authorization = up to 10 million shares of BD common stock, in addition to the shares that remain available under the board's previous authorization in 2021 | span gate: value not verbatim in filing | Feb 5, 2025 |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error